CanSino Biologics Inc. CJH.F Stock
CanSino Biologics Inc. Price Chart
CanSino Biologics Inc. CJH.F Financial and Trading Overview
| CanSino Biologics Inc. stock price | 2.04 EUR |
| Previous Close | 3.41 EUR |
| Open | 3.42 EUR |
| Bid | 3.37 EUR x N/A |
| Ask | 3.48 EUR x N/A |
| Day's Range | 3.42 - 3.42 EUR |
| 52 Week Range | 3.3 - 19.5 EUR |
| Volume | 9 EUR |
| Avg. Volume | 216 EUR |
| Market Cap | 1.73B EUR |
| Beta (5Y Monthly) | 0.640381 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.77 EUR |
| Forward Dividend & Yield | 0.12 (3.59%) |
| Ex-Dividend Date | July 13, 2022 |
| 1y Target Est | N/A |
CJH.F Valuation Measures
| Enterprise Value | -1354479872 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.716785 |
| Price/Book (mrq) | 0.12761748 |
| Enterprise Value/Revenue | -2.13 |
| Enterprise Value/EBITDA | 0.825 |
Trading Information
CanSino Biologics Inc. Stock Price History
| Beta (5Y Monthly) | 0.640381 |
| 52-Week Change | -66.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.5 EUR |
| 52 Week Low | 3.3 EUR |
| 50-Day Moving Average | 4.33 EUR |
| 200-Day Moving Average | 7.4 EUR |
CJH.F Share Statistics
| Avg. Volume (3 month) | 216 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 132.67M |
| Float | 151.48M |
| Short Ratio | N/A |
| % Held by Insiders | 26.69% |
| % Held by Institutions | 38.07% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -184.084% |
| Operating Margin (ttm) | -288.96% |
| Gross Margin | -78.51% |
| EBITDA Margin | -258.27% |
Management Effectiveness
| Return on Assets (ttm) | -9.92% |
| Return on Equity (ttm) | -15.95% |
Income Statement
| Revenue (ttm) | 635.79M EUR |
| Revenue Per Share (ttm) | 2.58 EUR |
| Quarterly Revenue Growth (yoy) | -79.90% |
| Gross Profit (ttm) | -183707000 EUR |
| EBITDA | -1642119552 EUR |
| Net Income Avi to Common (ttm) | -1170391040 EUR |
| Diluted EPS (ttm) | -0.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.38B EUR |
| Total Cash Per Share (mrq) | 21.8 EUR |
| Total Debt (mrq) | 2.72B EUR |
| Total Debt/Equity (mrq) | 38.39 EUR |
| Current Ratio (mrq) | 2.794 |
| Book Value Per Share (mrq) | 26.791 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1598801024 EUR |
| Levered Free Cash Flow (ttm) | -2382917120 EUR |
Profile of CanSino Biologics Inc.
| Country | Germany |
| State | N/A |
| City | Tianjin |
| Address | 401-420, Biomedical Park |
| ZIP | N/A |
| Phone | 400 922 2099 |
| Website | https://www.cansinotech.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 2291 |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Q&A For CanSino Biologics Inc. Stock
What is a current CJH.F stock price?
CanSino Biologics Inc. CJH.F stock price today per share is 2.04 EUR.
How to purchase CanSino Biologics Inc. stock?
You can buy CJH.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CanSino Biologics Inc.?
The stock symbol or ticker of CanSino Biologics Inc. is CJH.F.
Which industry does the CanSino Biologics Inc. company belong to?
The CanSino Biologics Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does CanSino Biologics Inc. have in circulation?
The max supply of CanSino Biologics Inc. shares is 498.65M.
What is CanSino Biologics Inc. Price to Earnings Ratio (PE Ratio)?
CanSino Biologics Inc. PE Ratio is now.
What was CanSino Biologics Inc. earnings per share over the trailing 12 months (TTM)?
CanSino Biologics Inc. EPS is -0.77 EUR over the trailing 12 months.
Which sector does the CanSino Biologics Inc. company belong to?
The CanSino Biologics Inc. sector is Healthcare.